Committed to helping patients with GU cancers live longer and better lives #theranostics ☢️ | research @pros_tic @gu_onc @austinurology
Melbourne, Victoria
Joined February 2022
- Tweets491
- Following548
- Followers268
- Likes4.2K
David Chen retweeted
(PRIMARY2 Trial) 🚨 @ButeauJames: PSMA-11 PET scan after an equivocal mpMRI (PI-RADS 2/3) cuts TP prostate biopsies by 50%. By using PRIMARY score, avoiding biopsies for PSMA-ve men and only targeted biopsies for PSMA-positive men—was non-inferior🔬👨⚕️ #ProstateCancer #EAU26 #pcsm
David Chen retweeted
Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. uroweb.org/news/scan-that-ma…
David Chen retweeted
1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum!
Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA.
bit.ly/4nzJRyV
Thanks to @LouiseKostos Heidi Fettke @PeterMacCC
David Chen retweeted
Early stable or rising PSA does not preclude subsequent biochemical or pain response with additional cycles of ¹⁷⁷Lu-PSMA-617 treatment. ow.ly/MXYY50Xc7eB
#NuclearMedicine #ProstateCancer #RPTherapy @davcmed @DrMHofman @AzadOncology
David Chen retweeted
The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active.
✅ No dose-limiting toxicities
💪 PSA-50% decline in 55%
🧬 Supports future α+β theranostic combos.
🔗 authors.elsevier.com/a/1lyc6…
Congrats @LouiseKostos: what an amazing PhD!
Thank-you to @PCF_Science @pros_tic @Bayer for funding & support, co-senior author @AzadOncology, all the co-authors, wider village of contributors and most importantly our patients and their families for participating.
David Chen retweeted
Shaping the future of Lu-177 PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key?
authors.elsevier.com/a/1lsTb…
@AzadOncology @Annals_Oncology #PSMAfore
David Chen retweeted
The hardest lessons after training aren’t always in the OR or clinic.
🙏 I wrote this essay for anyone navigating their first year as an attending.
“Unseen Scars” in @JAMA_current
🔗jamanetwork.com/journals/jam…
David Chen retweeted
#PRIMARY2 was a rather crazy (ambitious) idea a few years ago: run of randomised trial of 660 patients to determine if PSMA PET can improve DIAGNOSIS of prostate cancer in selected men with uncertain findings on MRI, potentially reducing the need for painful biopsies.
Recruitment has completed thanks to the enthusiasm and dedication from @drlouiseemmett @DrDanielMoon @ButeauJames and the many many urologists & nuclear medicine specialists around Australia who make this happen. Thanks to all the participants and our funders @PCF_Science @pros_tic @StVincentClinic @ANZUPtrials
Clinical trial protocol here:
pubmed.ncbi.nlm.nih.gov/3806…
First results 2026...
A clinical trial assessing a less invasive way to diagnose early #prostatecancer has just recruited its 660th, and final, patient. Read more about the PRIMARY2 trial - co-led by St Vincent's Hospital in Sydney and @pros_tic at Peter Mac - here: petermac.org/about-us/news-a…
David Chen retweeted
Augerlicious: Terbium-161 Double Punch to Cancer Cells FREE WEBINAR
Coming up Sep 17/18 !!! Don't miss it, register now: link.prostic.org/webinar
Is Terbium-161 superior to Lutetium-177? You'll hear about the latest clinical trials, experience and translational research from world leaders. Is Auger/beta combo better than alpha?
@PCF_Science @pros_tic @gu_onc
David Chen retweeted
Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. @DrMHofman @PeterMacCC joins Oliver Sartor, MD @EJHospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > bit.ly/46AXlG8
David Chen retweeted
Following a recent EOI process, @BJUIjournal have announced the new Editor for the BJUI USANZ Supplement. The role will be shared between @drMPerera and A/Prof Matthew Roberts.
We thank the outgoing editor @lawrentschuk for his ten years of service to USANZ and Urology.
David Chen retweeted
Ambushed by these two rad oncs @_ShankarSiva @DrAndrewLoblaw Sounded like they were taking me to a surgical technology launch but it was a CyberKNIFE launch! Robotic radio-surgery they say #notarealknife but impressive kit! @drMPerera @davcmed. GU Cast coming soon! @gu_onc
David Chen retweeted
While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4m3Eesv @AlexSherryMD @oncology_bg @PavlosMsaouel @ebludmir
David Chen retweeted
It gets easier.
Also, if you jog super slow the first mile, then everything after that is a lot easier. Just give your body some time to wake up and get into the rhythm of it. A lot of people push too hard right away, and then get burned out before they ever really got going.
David Chen retweeted
UPDATED! The definitive systematic reviews of PSMA PET/CT in @EUplatinum. Mazzone et al taking over from Perera et al. We discuss with @elio_mazzone @Albert0Briganti @drMPerera youtu.be/7nIaOPEzxKY
David Chen retweeted
🎗️ Oncology for the Non-Oncologist 🎗️
Thread: Oncology Emergencies You Can’t Miss
Interns listen up - 🧵
David Chen retweeted
🚨Detecting cribriform & IDC on MRI-guided prostate biopsy among pts w/ GG2-3 #prostatecancer🚨
👏First-author @RaevenGrant @dgsomucla just out in @JournalCancer
👉641 pts & 1186 GG2-3 tumors on MRI-guided biopsy
🔬Sensitivity for detecting cribriform, IDC, or either is poor: 22%, 27%, & 29%, respectively
💡As enthusiasm for surveillance for pts w/ GG2-3 grows, improving out ability to detect high-risk histologies will be paramount!
@CS_Urology @UCLAHealthJCCC @CSCancerCenter @UclaUrology @TimDaskivich @PCFnews @urotoday @UrologyTimes @pranavmovva
🔗shorturl.at/D40Qt
